KalVista Pharmaceuticals, Inc. financial data

Symbol
KALV on Nasdaq
Industry
Pharmaceutical Preparations
Location
55 Cambridge Parkway, Suite 901 E, Cambridge, MA
State of incorporation
DE
Fiscal year end
April 30
Former names
Carbylan Therapeutics, Inc. (to 11/21/2016), Carbylan Biosurgery, Inc (to 1/3/2013), Carbylan Biosurgery Inc (to 12/29/2005)
Latest financial report
10-Q - Q3 2024 - Dec 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 779 % -29.1%
Return On Equity -104 % -54.8%
Return On Assets -88.1 % -50.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.4M shares +43%
Common Stock, Shares, Outstanding 43.3M shares +25.7%
Entity Public Float 273M USD +128%
Common Stock, Value, Issued 43K USD +26.5%
Weighted Average Number of Shares Outstanding, Basic 46.7M shares +35.1%
Weighted Average Number of Shares Outstanding, Diluted 46.7M shares +35.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 91M USD +10.4%
General and Administrative Expense 80.6M USD +130%
Operating Income (Loss) -172M USD -46.1%
Nonoperating Income (Expense) 15.2M USD -9.99%
Net Income (Loss) Attributable to Parent -156M USD -55.5%
Earnings Per Share, Basic -3.68 USD/shares -21.5%
Earnings Per Share, Diluted -3.68 USD/shares -21.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.6M USD -27.9%
Assets, Current 152M USD +18.4%
Property, Plant and Equipment, Net 2.04M USD -18.5%
Operating Lease, Right-of-Use Asset 5.86M USD -19.7%
Other Assets, Noncurrent 662K USD +96.4%
Assets 161M USD +15.9%
Accounts Payable, Current 5.2M USD +6.17%
Employee-related Liabilities, Current 6.98M USD +81.1%
Accrued Liabilities, Current 15.4M USD +31.8%
Liabilities, Current 22.2M USD +24.9%
Operating Lease, Liability, Noncurrent 4.68M USD -28.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.7M USD +22%
Retained Earnings (Accumulated Deficit) -552M USD -39.5%
Stockholders' Equity Attributable to Parent 134M USD +17.1%
Liabilities and Equity 161M USD +15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.2M USD -50.5%
Net Cash Provided by (Used in) Financing Activities 3M USD +1371%
Net Cash Provided by (Used in) Investing Activities 37.2M USD +89.5%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 43.3M shares +25.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 59K USD
Deferred Tax Assets, Valuation Allowance 58.5M USD +29.3%
Deferred Tax Assets, Gross 60M USD +27.5%
Operating Lease, Liability 7.32M USD -11.1%
Payments to Acquire Property, Plant, and Equipment 21K USD +250%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -156M USD -57.7%
Lessee, Operating Lease, Liability, to be Paid 7.47M USD -22.8%
Property, Plant and Equipment, Gross 5.94M USD +0.56%
Operating Lease, Liability, Current 1.54M USD +33.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.61M USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.77M USD -0.23%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.68M USD -27.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.6M USD -13.2%
Deferred Tax Assets, Operating Loss Carryforwards 50.2M USD +40.2%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 769K USD -58.3%
Depreciation, Depletion and Amortization 224K USD +16.1%
Deferred Tax Assets, Net of Valuation Allowance 1.43M USD -18.8%
Share-based Payment Arrangement, Expense 3.04M USD -6.58%